Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease

Xiang, Hua; Sawada, Jun; Svenungsson, Elisabet; Hurt-Camejo, Eva; Jensen‐Urstad, Kerstin; Angelin, Bo; Båvenholm, Peter; Frostegård, Johan

doi:10.1080/03009740802541470

Cited by 26 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with a possible reduction/dysfunction of the small HDL populations specific for these transporters9 and with a shift to larger HDL, typical acceptors for SR-BI-presented cholesterol, supported also by the much stronger correlation between SR-BI-mediated CEC and total serum HDL levels that we found in SLE compared to controls and RA patients. Indeed, HDL structural alterations described in SLE include size increase 39 40. So, while a similar deficit in the cumulative contribute of ABCG1 and SR-BI-mediated CEC was found in RA and SLE with respect to controls, the profoundly altered ratio between these two pathway-mediated CEC in SLE further supports a complex derangement in the HDL functional pattern specific for this disease, even in presence of normal serum HDL levels.…”

Section: Discussionmentioning

confidence: 79%

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 79%

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This pattern is consistent with a possible reduction/dysfunction of the small HDL populations (Favari et al 2009) and a shift to larger HDL, typical acceptors of cholesterol effluxed by SR-BI. Indeed, HDLs of SLE patients were found increased in size (Hua et al 2009;Juárez-Rojas et al 2008). The impaired ABCA1-and ABCG1-mediated CEC in SLE patients may have a great impact because cholesterol efflux not only opposes lipid deposition in vessels but is also crucial for the modulation of macrophage, endothelial, and T-cell inflammatory functions (Prosser et al 2012;Yvan-Charvet et al 2010a, b).…”

Section: Systemic Lupus Erythematosus (Sle)mentioning

confidence: 99%

Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions

Montecucco

Favari

Norata

et al. 2014

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.

show abstract

“…A retrospective analysis carried out by Bessant et al demonstrated that patients with SLE just prior to a CVD event (MI, angina, cerebrovascular accident [CVA] or peripheral vascular disease) were more likely to have the presence of lupus anticoagulant compared with patients with SLE without CVD, after controlling for disease duration [62]. The presence of antiphospholipid antibodies was an independent predictor of vascular events in multiple prior studies on SLE patients [70,71]. A specific antiphospholipid antibody, anti-β-2-glycoprotein I antibody, has also been associated with increased risk of acute coronary syndrome in the general population [72].…”

Section: Lupus-specific Variablesmentioning

confidence: 99%

“…Hua et al revealed further abnormalities in patients with SLE when they showed that higher VLDL concentrations differentiated SLE patients with CVD from SLE patients who did not have CVD and from general population controls. Interestingly, LDL did not differ significantly between study groups and neither did small, dense LDL [70]. As discussed above, the role of corticosteroids in this lipid profile is not clear.…”

Section: Lupus-specific Variablesmentioning

confidence: 99%

Management of cardiovascular complications in systemic lupus erythematosus

Skamra¹,

Ramsey‐Goldman

2010

International Journal of Clinical Rheumatology

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Patients with SLE have an excess risk compared with the general population; this is particularly pronounced in younger women with SLE who have an excess risk of over 50-fold compared with population controls. There is a higher prevalence of subclinical atherosclerosis in patients with SLE compared with controls, as demonstrated by a variety of imaging modalities discussed in this review. The causality of the excess risk of CVD and subclinical atherosclerosis is multifactorial in patients with SLE. While traditional risk factors play a role, after controlling for the traditional Framingham risk factors, the excess risk is still 7.5-fold greater than the general population. This review will also cover novel cardiovascular risk factors and some SLEspecific variables that contribute to CVD risk. This review discusses the risk factor modification and the evidence available for treatment of these risk factors in SLE. There have not yet been any published randomized, controlled trials in patients with SLE with respect to CVD risk factor modifications. Thus, the treatment and management recommendations are based largely on published guidelines for other populations at high risk for CVD. Keywordscardiac imaging; cardiovascular disease; cardiovascular risk factors; subclinical atherosclerosis; systemic lupus erythematosusIn the last few decades, the prognosis of patients with systemic lupus erythematosus (SLE) has improved immensely. In the 1950s, the 5-year survival rate for SLE was approximately 50% according to a study performed in Toronto, Canada. Subsequent studies have found 5-year survival rates of 90% in patients with SLE [1]. A bimodal mortality pattern was first described in 1976 by Urowitz et al. in the Toronto Lupus cohort. Septicemia in the setting of high-dose prednisone was identified as an early cause of death in patients with more active SLE. Later in the disease course, death was associated with inactive SLE, long duration of prednisone therapy and myocardial infarction (MI) due to atherosclerotic heart disease [2]. More recent data from a large international cohort revealed a 60% decrease in the standardized all-cause mortality rates (SMR) from 1970-1979 (SMR: 4.9) to 1990. However, the SMR trend for cardiovascular disease (including heart disease, arterial disease and stroke) did not decline from 1970 to 2001 [3]. A Swedish cohort followed from 1964 to 1994 demonstrated similar findings of improved overall survival for patients with SLE over the last two decades, but the risk of cardiovascular death remained (by 1985-1994 NIH Public Access Author ManuscriptInt J Clin Rheumtol. Author manuscript; available in PMC 2010 December 1. Published in final edited form as:Int J Clin Rheumtol. This review will discuss the increased risk of CVD observed in patients with SLE, the role of traditional cardiovascular risk factors, the role of novel risk factors (some of which are lu...

show abstract

Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE‐related cardiovascular disease

Abstract: sdLDL was not increased and SLE cases and SLE controls had decreased levels of sHDL. VLDL differentiates between SLE cases and SLE controls. The lipid pattern in SLE-related CVD was thus not similar to the pattern seen in diabetes or in CVD in general.

Cited by 26 publications

References 34 publications

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions

Management of cardiovascular complications in systemic lupus erythematosus

Contact Info

Product

Resources

About